key: cord-0712619-ntgwi9i5
authors: Morello, William; Vianello, Federica Alessandra; Proverbio, Emanuele; Montini, Giovanni
title: Response to Krishnasamy et al
date: 2022-01-10
journal: Pediatr Nephrol
DOI: 10.1007/s00467-021-05400-5
sha: 2eefeecc8437a538aafb1391a73beaf543f6225d
doc_id: 712619
cord_uid: ntgwi9i5

nan

We thank Dr. Krishnasamy and co-authors for their letter highlighting their experience with COVID-19 in India [1] in response to our review and recommendations on the management of idiopathic nephrotic syndrome (INS) during the pandemic [2] . As the authors stated, this publication only became available after our systematic search of the literature was performed and therefore it was not included in the review.

In their paper [1] , which reported retrospectively collected data from 4 pediatric nephrology centers in New Delhi, the authors describe a mortality rate of 4.5% in children with INS and SARS-CoV-2 infection (2/44), and they identify a concomitant relapse as a predictor of a worse outcome. Their findings are very different from the data summarized in our review [2] and the results of a new search performed on 30 November 2021, including the first collaborative European report and a national study performed by the Italian Society of Paediatric Nephrology.

There is only 1 other collaborative study reporting a similar mortality rate (3.5%) in paediatric patients affected by kidney diseases and SARS-CoV-2 infection [3] , but the underlying clinical condition of the fatal cases is not specified (INS vs. other kidney diseases). Interestingly, all deaths were in developing countries, with 3 out of 4 in India.

The unexpected dismal outcome of INS patients reported by Krishnasamy et al. may be related to a distinct genetic background, which is believed to influence the course of SARS-CoV-2 infection, or a different approach to INS relapses and COVID-19 themselves. Therefore, it will be crucial to understand if similar complications will be reported in the near future by others, and how this mortality rate compares to that expected for children with SARS-CoV-2 infection or those with INS relapses in India.

However, according to the available literature, it is still correct to affirm that the course of SARS-CoV-2 infection is mostly mild in children with INS, even during relapses.

SARS-CoV-2 infection may be complicated by acute kidney injury or tubular damage, in children with and without underlying kidney conditions. Indeed, our recommendations suggest monitoring SARS-CoV-2 infection for signs of relapse in children with INS and support SARS-CoV-2 vaccination in this population. Moreover, we recommend considering hospital admission in the case of clinical worsening [2] .

On this basis, we believe our recommendations are still effective and helpful for the management of children with INS during the pandemic.

SARS-CoV-2 infection in children with chronic kidney disease

COVID-19 and idiopathic nephrotic syndrome in children: systematic review of the literature and recommendations from a highly affected area

COVID-19 in children treated with immunosuppressive medication for kidney diseases